Delcath Systems, Inc. to Participate in Oppenheimer Fall MedTech Summit on Thursday, November 12, 2020
03 November 2020 - 8:01AM
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology
company focused on liver-directed treatment of primary and
metastatic cancers, today announced management will participate in
the Oppenheimer Fall MedTech Summit on Thursday, November 12,
2020.
Management will be available for virtual one-on-one meetings
during the conference. To schedule a meeting with management,
please contact your conference representative
or James@HaydenIR.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
Our investigational product Melphalan Hydrochloride for Injection
for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is
designed to administer high-dose chemotherapy to the liver while
minimizing systemic exposure and associated side effects. In
addition to the Phase 3 FOCUS Trial which is evaluating the safety
and efficacy of Melphalan/HDS to treat patients with
hepatic-dominant ocular melanoma, we are also evaluating the
potential for Melphalan/HDS to treat other forms of metastatic
liver cancers. Melphalan/HDS has not been approved by the U.S. Food
& Drug Administration (FDA) for sale in the U.S. In Europe, our
system is marketed under the trade name Delcath CHEMOSAT® Hepatic
Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and
used at major medical centers to treat a wide range of cancers of
the liver. CHEMOSAT is being marketed under an exclusive licensing
agreement with medac GmbH, a privately held multi-national
pharmaceutical company headquartered in Germany that specializes in
the treatment and diagnosis of oncological, urological and
autoimmune diseases.
Contact:
Hayden IRJames Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jul 2023 to Jul 2024